Current Report Filing (8-k)
May 04 2017 - 7:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 4, 2017
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-30929
|
|
13-4087132
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
One Marina Park Drive, 12
th
Floor
Boston, Massachusetts 02210
(Address of Principal Executive Offices)
(617)
466-3500
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act.
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act.
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act.
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act.
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or
Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
|
Results of Operations and Financial Condition.
|
On May 4, 2017, Keryx
Biopharmaceuticals, Inc. (Keryx) issued a press release announcing its results of operations for the quarter ended March 31, 2017. Keryx also announced that on May 4, 2017 at 8:00 a.m. ET, it will host an investor conference
call to discuss its first quarter 2017 financial results and provide a business update. A copy of such press release is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference. A copy of the investor presentation to be
used on the investor conference call is being furnished as Exhibit 99.2 to this report and is incorporated herein by reference.
The
information set forth in Exhibits 99.1 and 99.2 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of
that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
filing.
Item 9.01.
|
Financial Statements And Exhibits.
|
The following exhibits are furnished herewith:
|
|
|
99.1
|
|
Press release issued by Keryx Biopharmaceuticals, Inc., dated May 4, 2017.
|
|
|
99.2
|
|
Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on May 4, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Keryx Biopharmaceuticals, Inc.
|
|
|
|
|
(Registrant)
|
Date: May 4, 2017
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Brian Adams
|
|
|
|
|
|
|
Brian Adams
|
|
|
|
|
|
|
General Counsel and Corporate Secretary
|
INDEX TO EXHIBITS
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press release issued by Keryx Biopharmaceuticals, Inc., dated May 4, 2017.
|
|
|
99.2
|
|
Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on May 4, 2017.
|
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2024 to May 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From May 2023 to May 2024